Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

retrospective cohort study based on electronic medical records data to compare the incidence of ORC in adults (≥24 years) living with obesity and diabetes who were treated with a first-generation ...

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...

GLP-1 Receptor Agonist Market Demand 2025 BURLINGAME ... images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN ...

In clinical trials, semaglutide proved to be superior to placebo, with weight loss reaching 15%, suggesting its superiority over other non-GLP-1 RA anti ... undertreated in comparison to its ...

A systematic review and meta-analysis published in JAMA Psychiatry found little evidence of increased suicidality among glucagon-like peptide 1 receptor agonist (GLP-1 RA) recipients in ... as ...

Among adults with diabetes or obesity, the rate of suicide is unlikely to increase with the use of GLP-1 RAs. A systematic review and meta-analysis published in JAMA Psychiatry found little ...